As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > ORGANIZATION
ORGANIZATION
- New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan
July 19, 2017
- EFPIA Japan to Provide 1 Million Yen to Support Patients’ Organizations
July 5, 2017
- Generic Use Rate at 65.5% in FY2016: JGA
June 30, 2017
- JMA Announces Endorsement for Chuikyo Rep Replacements
June 26, 2017
- FPMAJ Weighs Refined Version of “Similar Treatment Comparison” Pricing Method
June 20, 2017
- FPMAJ “Not Opposed” to Company Requirements for Receiving Price Maintenance Premium: Kamoya
June 20, 2017
- Reflecting Results of CEA in NHI Prices at Time of Listing Will Be Difficult: FPMAJ Report
June 20, 2017
- FPMAJ Calls for “Cautious” Discussions on Reduction of Price Band for Generic Drugs
June 19, 2017
- FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
- JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
- JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
- Membership of Japan Biosimilar Association to Reach 20 Companies in Near Future
June 7, 2017
- Public, Private Donors Put Up US$200-Plus Million for GHIT’s 2nd-Phase Work
June 5, 2017
- Japan Drug Market Could Shrink at CAGR of -2.5% If Price Maintenance Premium Scrapped: EFPIA
June 1, 2017
- JGA Ups Its Lobbying Efforts to Prevent Further Reduction in Price Bands for Generics
June 1, 2017
- Maker FTC Sanctions Member Company for Violating Fair Competition Code
May 30, 2017
- Wholesale Industry FTC to Discuss Prohibiting Free-of-Charge Inventory Transfers between Pharmacies
May 30, 2017
- JPMA Will Be Watching Discussions on Eligibility Criteria for Companies to Receive Price Maintenance Premium
May 29, 2017
- Suzuki to Serve His 3rd Term as JPWA Chief
May 26, 2017
- Japan Microbiome Consortium Inaugurated by Drug Makers to Promote Drug Discovery Research
May 25, 2017
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…